Cargando…

Opiate Antagonists for Chronic Pain: A Review on the Benefits of Low-Dose Naltrexone in Arthritis versus Non-Arthritic Diseases

Chronic pain conditions create major financial and emotional burdens that can be devastating for individuals and society. One primary source of pain is arthritis, a common inflammatory disease of the joints that causes persistent pain in affected people. The main objective of pharmacological treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Dara, Praneet, Farooqui, Zeba, Mwale, Fackson, Choe, Chungyoul, van Wijnen, Andre J., Im, Hee-Jeong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296090/
https://www.ncbi.nlm.nih.gov/pubmed/37371715
http://dx.doi.org/10.3390/biomedicines11061620
_version_ 1785063575425908736
author Dara, Praneet
Farooqui, Zeba
Mwale, Fackson
Choe, Chungyoul
van Wijnen, Andre J.
Im, Hee-Jeong
author_facet Dara, Praneet
Farooqui, Zeba
Mwale, Fackson
Choe, Chungyoul
van Wijnen, Andre J.
Im, Hee-Jeong
author_sort Dara, Praneet
collection PubMed
description Chronic pain conditions create major financial and emotional burdens that can be devastating for individuals and society. One primary source of pain is arthritis, a common inflammatory disease of the joints that causes persistent pain in affected people. The main objective of pharmacological treatments for either rheumatoid arthritis (RA) or osteoarthritis (OA) is to reduce pain. Non-steroidal anti-inflammatory drugs, opioids, and opioid antagonists have each been considered in the management of chronic pain in arthritis patients. Naltrexone is an oral-activated opioid antagonist with biphasic dose-dependent pharmacodynamic effects. The molecule acts as a competitive inhibitor of opioid receptors at high doses. However, naltrexone at low doses has been shown to have hormetic effects and provides relief for chronic pain conditions such as fibromyalgia, multiple sclerosis (MS), and inflammatory bowel disorders. Current knowledge of naltrexone suggests that low-dose treatments may be effective in the treatment of pain perception in chronic inflammatory conditions observed in patients with either RA or OA. In this review, we evaluated the therapeutic benefits of low-dose naltrexone (LDN) on arthritis-related pain conditions.
format Online
Article
Text
id pubmed-10296090
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102960902023-06-28 Opiate Antagonists for Chronic Pain: A Review on the Benefits of Low-Dose Naltrexone in Arthritis versus Non-Arthritic Diseases Dara, Praneet Farooqui, Zeba Mwale, Fackson Choe, Chungyoul van Wijnen, Andre J. Im, Hee-Jeong Biomedicines Review Chronic pain conditions create major financial and emotional burdens that can be devastating for individuals and society. One primary source of pain is arthritis, a common inflammatory disease of the joints that causes persistent pain in affected people. The main objective of pharmacological treatments for either rheumatoid arthritis (RA) or osteoarthritis (OA) is to reduce pain. Non-steroidal anti-inflammatory drugs, opioids, and opioid antagonists have each been considered in the management of chronic pain in arthritis patients. Naltrexone is an oral-activated opioid antagonist with biphasic dose-dependent pharmacodynamic effects. The molecule acts as a competitive inhibitor of opioid receptors at high doses. However, naltrexone at low doses has been shown to have hormetic effects and provides relief for chronic pain conditions such as fibromyalgia, multiple sclerosis (MS), and inflammatory bowel disorders. Current knowledge of naltrexone suggests that low-dose treatments may be effective in the treatment of pain perception in chronic inflammatory conditions observed in patients with either RA or OA. In this review, we evaluated the therapeutic benefits of low-dose naltrexone (LDN) on arthritis-related pain conditions. MDPI 2023-06-02 /pmc/articles/PMC10296090/ /pubmed/37371715 http://dx.doi.org/10.3390/biomedicines11061620 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Dara, Praneet
Farooqui, Zeba
Mwale, Fackson
Choe, Chungyoul
van Wijnen, Andre J.
Im, Hee-Jeong
Opiate Antagonists for Chronic Pain: A Review on the Benefits of Low-Dose Naltrexone in Arthritis versus Non-Arthritic Diseases
title Opiate Antagonists for Chronic Pain: A Review on the Benefits of Low-Dose Naltrexone in Arthritis versus Non-Arthritic Diseases
title_full Opiate Antagonists for Chronic Pain: A Review on the Benefits of Low-Dose Naltrexone in Arthritis versus Non-Arthritic Diseases
title_fullStr Opiate Antagonists for Chronic Pain: A Review on the Benefits of Low-Dose Naltrexone in Arthritis versus Non-Arthritic Diseases
title_full_unstemmed Opiate Antagonists for Chronic Pain: A Review on the Benefits of Low-Dose Naltrexone in Arthritis versus Non-Arthritic Diseases
title_short Opiate Antagonists for Chronic Pain: A Review on the Benefits of Low-Dose Naltrexone in Arthritis versus Non-Arthritic Diseases
title_sort opiate antagonists for chronic pain: a review on the benefits of low-dose naltrexone in arthritis versus non-arthritic diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296090/
https://www.ncbi.nlm.nih.gov/pubmed/37371715
http://dx.doi.org/10.3390/biomedicines11061620
work_keys_str_mv AT darapraneet opiateantagonistsforchronicpainareviewonthebenefitsoflowdosenaltrexoneinarthritisversusnonarthriticdiseases
AT farooquizeba opiateantagonistsforchronicpainareviewonthebenefitsoflowdosenaltrexoneinarthritisversusnonarthriticdiseases
AT mwalefackson opiateantagonistsforchronicpainareviewonthebenefitsoflowdosenaltrexoneinarthritisversusnonarthriticdiseases
AT choechungyoul opiateantagonistsforchronicpainareviewonthebenefitsoflowdosenaltrexoneinarthritisversusnonarthriticdiseases
AT vanwijnenandrej opiateantagonistsforchronicpainareviewonthebenefitsoflowdosenaltrexoneinarthritisversusnonarthriticdiseases
AT imheejeong opiateantagonistsforchronicpainareviewonthebenefitsoflowdosenaltrexoneinarthritisversusnonarthriticdiseases